• Sulfaphenazole-Derived Sulfonamides for TB

  2026-08-21

  Chen and colleagues used sulfaphenazole as a starting point for systematic sulfonamide optimization against Mycobacterium tuberculosis while targeting its CYP2C9 liability. Compound 10d combined reported antimycobacterial activity with weak CYP2C9 inhibition, providing a useful medicinal-chemistry precedent for balancing efficacy and drug–drug interaction risk.

• Methotrexate Workflows for Permeability Research

  2026-08-20

  Use Methotrexate as a mechanistic probe for DHFR inhibition, activated T-cell apoptosis, proliferation control, and immunosuppression. Pair cell-based experiments with IAM-LC or OT-CEC-MS to distinguish membrane interaction, intracellular persistence, and biological response.

• L. plantarum P101, AMPK, and Alcoholic Fatty Liver

  2026-08-20

  This 2025 study shows that Lactiplantibacillus plantarum P101 reduced alcohol-induced hepatic lipid accumulation in mice, with evidence that AMPK activation was required for the protective phenotype. By combining pharmacological pathway inhibition with gut microbiota profiling and serum metabolomics, the work connects probiotic intervention to a gut–liver metabolic mechanism while identifying candidate microbial and metabolite correlates.

• Dronedarone: Reading the KCa2 Assay Correctly

  2026-08-19

  Dronedarone (Multaq) is more than a broad antiarrhythmic comparator: its behavior in KCa2 channel assays helps researchers separate multi-ion-channel effects from atrial-selective mechanisms. This evidence-led guide connects assay interpretation, exposure relevance, and practical compound handling.

• Gap19: Selective Connexin 43 Hemichannel Workflow

  2026-08-19

  Gap19 enables researchers to separate Cx43 hemichannel signaling from gap junction communication in astrocyte, ischemia, and inflammatory assays. This workflow translates its peptide design, dose-response behavior, and delivery considerations into practical experiments with built-in controls for ATP release, macrophage polarization, and neuroprotection.

• Clarithromycin as a CYP3A Inhibitor

  2026-08-18

  Use Clarithromycin as a controlled CYP3A perturbation tool for enzyme assays, pharmacokinetic studies, and statin metabolism interaction experiments. This workflow pairs concentration-resolved inhibition with a CYP-independent comparator to separate pathway effects from broader changes in drug disposition.

• NADPH Oxidase ROS Activate L-Type Ca2+ Channels

  2026-08-18

  This study identifies L-type voltage-gated Ca2+ channels as the principal downstream route by which NADPH oxidase-derived ROS promote arterial contraction in early postnatal rats. Pharmacological comparisons show that Rho-kinase, PKC, and Src-kinase contribute to methoxamine contraction but are not required for the specific procontractile effect of NADPH oxidase-derived ROS.

• EZ Cap Cy5 Firefly Luciferase mRNA Assay Design

  2026-08-17

  EZ Cap Cy5 Firefly Luciferase mRNA enables researchers to separate mRNA localization from productive protein expression through paired Cy5 fluorescence and luciferase readouts. This article presents an assay-design framework that connects delivery chemistry, innate immune activation suppression, and quantitative translation analysis.

• Steroid Lysis of Protoplasts: Methods and Findings

  2026-08-17

  The 1965 study by Smith and Shay used lysozyme-generated Sarcina lutea protoplasts to distinguish steroid-associated membrane damage from effects involving the bacterial cell wall. Its protection experiments with polyamines, metal ions, uranyl nitrate, and surfactants provide a useful framework for interpreting membrane-lysis assays while highlighting the limits of inferring mechanism from optical readouts alone.

• Cy3-UTP for RNA Nanoparticle Assays

  2026-08-16

  Cy3-UTP enables direct visualization of labeled RNA during transcription, nanoparticle formulation, cellular uptake, and RNA detection workflows. Combined with stability and structure assays, it helps distinguish RNA delivery, particle association, and intracellular release rather than treating fluorescence as a standalone transfection readout.

• ERK5 in Vitamin D–Induced Myeloid Differentiation

  2026-08-15

  Wang et al. show that ERK5 and ERK1/2 make distinct contributions to 1α,25-(OH)2 vitamin D3-induced differentiation of HL60 and U937 myeloid leukemia cells. ERK5 inhibition altered CD11b and CD14 expression while producing cell-cycle arrest, revealing pathway-specific control that is not captured by treating MAPK signaling as a single linear module.

• Realgar, Ornithine, and Astrocyte Glycolysis

  2026-08-14

  This 2025 Advanced Science study identifies a liver–brain mechanism linking realgar-derived arsenic, hepatic OTC inhibition, ornithine accumulation, and ZBTB7A-mediated suppression of astrocyte glycolysis. Its multi-model design connects altered urea-cycle metabolism with frontal-lobe energy failure and behavioral impairment, providing a framework for studying arsenic-associated CNS toxicity.

• Engage & Evasion for EV MPS Escape

  2026-08-14

  The 2024 Journal of Nanobiotechnology study introduces a sequential extracellular vesicle strategy that first engages the mononuclear phagocyte system with CD47-low vesicles and then protects CD47-high therapeutic vesicles from uptake. This design reduced liver and spleen entrapment, increased circulating vesicle levels, and improved distribution to non-MPS organs, offering a useful framework for ischemic disease delivery.

• AMD-070 hydrochloride: CXCR4 Workflow Guide

  2026-08-13

  Build reproducible CXCR4 trafficking, signaling, and migration assays with AMD-070 hydrochloride, using practical concentration, timing, and control strategies. The workflow connects bench readouts to the phase 3 WHIM syndrome evidence while clearly separating translational findings from exploratory anti-HIV research.

• L-NAME Hydrochloride: Mechanism and Vascular Research

  2026-08-13

  L-NAME Hydrochloride, also called NG-nitro-L-arginine methyl ester, is a competitive nitric oxide synthase inhibitor used to reduce nitric oxide formation in vascular and cell-based experiments. Its reported activity, formulation properties, and dose ranges support controlled studies of vascular tone regulation, hypertension, and selected inflammation-related endpoints.

551 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page